Literature DB >> 12206675

Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding.

F Peter Guengerich1, Grover P Miller, Imad H Hanna, Martha V Martin, Serge Léger, Cameron Black, Nathalie Chauret, José M Silva, Laird A Trimble, James A Yergey, Deborah A Nicoll-Griffith.   

Abstract

Cytochrome P450 (P450) 2D6 was first identified as the polymorphic human debrisoquine hydroxylase and subsequently shown to catalyze the oxidation of a variety of drugs containing a basic nitrogen. Residue Asp301 has been characterized as being involved in electrostatic interactions with substrates on the basis of homology modeling and site-directed mutagenesis experiments [Ellis, S. W., Hayhurst, G. P., Smith, G., Lightfoot, T., Wong, M. M. S., Simula, A. P., Ackland, M. J., Sternberg, M. J. E., Lennard, M. S., Tucker, G. T., and Wolf, C. R. (1995) J. Biol. Chem. 270, 29055-29058]. However, pharmacophore models based on the role of Asp301 in substrate binding are compromised by reports of catalytic activity toward substrates devoid of a basic nitrogen, which have generally been ignored. We characterized a high-affinity ligand for P450 2D6, also devoid of a basic nitrogen atom, spirosulfonamide [4-[3-(4-fluorophenyl)-2-oxo-1-oxaspiro[4.4]non-3-en-4-yl]benzenesulfonamide], with K(s) 1.6 microM. Spirosulfonamide is a substrate for P450 2D6 (k(cat) 6.5 min(-)(1) for the formation of a syn spiromethylene carbinol, K(m) 7 microM). Mutation of Asp301 to neutral residues (Asn, Ser, Gly) did not substantially affect the binding of spirosulfonamide (K(s) 2.5-3.5 microM). However, the hydroxylation of spirosulfonamide was attenuated in these mutants to the same extent (90%) as for the classic nitrogenous substrate bufuralol, and the effect of the D301N substitution was manifested on k(cat) but not K(m). Analogues of spirosulfonamide were also evaluated as ligands and substrates. Analogues in which the sulfonamide moiety was modified to an amide, thioamide, methyl sulfone, or hydrogen were ligands with K(s) values of 1.7-32 microM. All were substrates, and the methyl sulfone analogue was oxidized to the syn spiromethylene carbinol analogue of the major spirosulfonamide product. The D301N mutation produced varying changes in the oxidation patterns of the spirosulfonamide analogues. The peptidometic ritonavir and the steroids progesterone and testosterone had been reported to be substrates for P450 2D6, but the affinities (K(s)) were unknown; these were estimated to be 1.2, 1.5, and 15 microM, respectively (cf. 6 microM for the classic substrate bufuralol). The results are consistent with a role of Asp301 other than electrostatic interaction with a positively charged ligand. H-Bonding or electrostatic interactions probably enhance binding of some substrates, but our results show that it is not required for all substrates and explain why predictive models fail to recognize the proclivity for many substrates, especially those containing no basic nitrogen.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12206675     DOI: 10.1021/bi020341k

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  16 in total

1.  Molecular analysis and modeling of inactivation of human CYP2D6 by four mechanism based inactivators.

Authors:  Mara Livezey; Leslie D Nagy; Laura E Diffenderfer; Evan J Arthur; David J Hsi; Jeffrey M Holton; Laura Lowe Furge
Journal:  Drug Metab Lett       Date:  2012-03

2.  Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration.

Authors:  Julius O Soyinka; Cyprian O Onyeji; Sharon I Omoruyi; Adegbenga R Owolabi; Pullela V Sarma; James M Cook
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

3.  Human liver mitochondrial cytochrome P450 2D6--individual variations and implications in drug metabolism.

Authors:  Michelle Cook Sangar; Hindupur K Anandatheerthavarada; Weigang Tang; Subbuswamy K Prabu; Martha V Martin; Miroslav Dostalek; F Peter Guengerich; Narayan G Avadhani
Journal:  FEBS J       Date:  2009-05-11       Impact factor: 5.542

4.  Molecular properties and CYP2D6 substrates: central nervous system therapeutics case study and pattern analysis of a substrate database.

Authors:  Laura K Chico; Heather A Behanna; Wenhui Hu; Guifa Zhong; Saktimayee Mitra Roy; D Martin Watterson
Journal:  Drug Metab Dispos       Date:  2009-08-06       Impact factor: 3.922

5.  Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity.

Authors:  Jack U Flanagan; Lesley A McLaughlin; Mark J I Paine; Michael J Sutcliffe; Gordon C K Roberts; C Roland Wolf
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

6.  Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism.

Authors:  Rayomand J Unwalla; Jason B Cross; Sumeet Salaniwal; Adam D Shilling; Louis Leung; John Kao; Christine Humblet
Journal:  J Comput Aided Mol Des       Date:  2010-04-02       Impact factor: 3.686

7.  IDSite: An accurate approach to predict P450-mediated drug metabolism.

Authors:  Jianing Li; Severin T Schneebeli; Joseph Bylund; Ramy Farid; Richard A Friesner
Journal:  J Chem Theory Comput       Date:  2011-11-08       Impact factor: 6.006

8.  Crystal Structures of Drug-Metabolizing CYPs.

Authors:  D Fernando Estrada; Amit Kumar; Christopher S Campomizzi; Natalie Jay
Journal:  Methods Mol Biol       Date:  2021

Review 9.  Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions.

Authors:  J-D Maréchal; C A Kemp; G C K Roberts; M J I Paine; C R Wolf; M J Sutcliffe
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

10.  Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.

Authors:  Jack U Flanagan; Jean-Didier Maréchal; Richard Ward; Carol A Kemp; Lesley A McLaughlin; Michael J Sutcliffe; Gordon C K Roberts; Mark J I Paine; C Roland Wolf
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.